Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesPraxis Precision Medicines Inc

Praxis Precision Medicines Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
346.21 USD 8.62 ( 2.55%)
Last update at 2026-11-11T21:00:00Z
VOLUME
715572
Market Cap
773.45M

Momentum Score

…

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
334.17
Low
351.64
High
52 Week Price Range
12.45
Low
67.21
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing precision therapies for neuropsychiatric and neurological disorders, focusing on GABAergic and ion-channel targets to modulate neuronal excitability. Major long-term growth drivers include clinical trial progress of its pipeline, application of mechanism-based, genetically informed approaches, and potential partnerships or approvals that could expand indications; investors may find the company attractive for its targeted neuroscience platform addressing unmet CNS needs.

Principal investment risks include clinical and regulatory failure, significant funding requirements that could dilute equity, and intense competition in CNS therapeutics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
337.59
Dividend Yield
-
Revenue TTM
2.19M
Revenue Per Share
0.24
Gross Profit TTM
0.00M
Debt / Equity
0.04
ROE
-85.25%
Net Debt
-78.81M
ROCE
-298.35%
Diluted EPS TTM
-11.27

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -214.03M -167.06M -61.83M -35.60M -26.40M
Net income -213.07M -166.88M -61.82M -35.51M -26.54M
Selling general administrative 59.95M 47.08M 16.99M 6.23M 3.90M
Reconciled depreciation 0.42M 0.18M 0.05M 0.04M 0.00M
Ebit -215.41M -167.51M -62.02M -35.79M -26.27M
Ebitda -214.99M -167.33M -61.97M -35.56M -26.27M
Depreciation and amortization 0.42M 0.18M 0.05M 0.23M 0.00M
Non operating income net other 0.96M 0.27M 0.14M - -
Operating income -214.99M -167.33M -61.97M -35.79M -22.72M
Other operating expenses 214.99M 167.33M 61.97M 35.79M 22.72M
Interest expense 0.42M 0.18M 0.19M 0.00M 0.13M
Tax provision 0.00M 0.00M -0.01M -0.08M 0.13M
Interest income - - 0.14M 0.19M 0.09M
Net interest income - - 0.14M 0.19M -0.04M
Income tax expense -0.96M -0.18M -0.01M -0.08M 0.13M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 214.99M 167.33M 61.97M 35.79M 22.72M
Total other income expense net 0.96M 0.27M 0.14M 0.19M -3.65M
Net income from continuing ops -214.03M -167.06M -61.82M -35.51M -26.54M
Net income applicable to common shares -214.03M -167.06M -70.32M -40.68M -29.22M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 87.95M 115.13M 292.75M 303.18M 47.69M
Other current assets 3.58M 10.35M 11.50M 5.72M 0.68M
Total liab 18.28M 39.02M 41.94M 15.72M 7.58M
Total stockholder equity 69.67M 76.11M 250.81M 287.46M 40.11M
Other current liab 7.42M 14.85M 22.53M 10.87M 3.46M
Common stock 0.01M 0.01M 0.01M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.00M 0.00M
Retained earnings -653.92M -530.64M -316.62M -149.55M -81.01M
Other liab - 2.18M - - -
Other assets - 0.42M 0.47M 0.77M 0.62M
Cash 81.30M 61.62M 138.70M 296.61M 44.81M
Total current liabilities 15.75M 35.52M 37.62M 15.72M 6.82M
Current deferred revenue 1.39M 5.00M - - -
Net debt -78.81M -57.11M -134.39M -295.85M -43.36M
Short term debt 1.13M 1.00M 4.31M 0.76M 0.70M
Short long term debt total 2.50M 4.50M 4.31M 0.76M 1.46M
Other stockholder equity 723.58M 606.92M 567.60M 437.01M -121.08M
Property plant equipment - 0.97M 4.87M 0.84M 1.58M
Total current assets 84.88M 110.84M 287.41M 302.33M 45.50M
Net tangible assets - 76.11M 250.81M 287.46M -81.01M
Short term investments 0.00M 38.87M 137.21M - -
Accounts payable 5.82M 14.67M 10.78M 4.09M 2.67M
Accumulated other comprehensive income - -0.17M -0.18M -303.18M -0.04M
Common stock total equity - 0.01M 0.01M 0.00M 0.00M
Retained earnings total equity - -530.64M -316.62M -149.55M -
Non currrent assets other 0.42M 0.42M 0.47M 0.01M 0.62M
Non current assets total 3.07M 4.29M 5.34M 0.85M 2.20M
Capital lease obligations 2.50M 3.50M 4.31M 0.76M 1.46M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 97.33M -139.47M -139.47M -0.10M -0.06M
Change to liabilities -6.57M 7.27M 0.96M -0.84M 1.67M
Total cashflows from investing activities 96.89M -140.52M 0.00M -0.10M -0.06M
Net borrowings - - - - 1.00M
Total cash from financing activities 10.46M 107.59M 304.42M 60.39M 37.80M
Change to operating activities -10.67M 8.87M 2.28M 1.58M -0.21M
Net income -214.03M -167.06M -61.82M -35.51M -26.54M
Change in cash -77.69M -157.49M 251.79M 26.86M 17.02M
Begin period cash flow 139.72M 297.21M 45.41M 18.55M 1.53M
End period cash flow 62.03M 139.72M 297.21M 45.41M 18.55M
Total cash from operating activities -185.04M -124.55M -52.62M -33.42M -20.72M
Issuance of capital stock 9.56M 105.71M 334.33M 60.39M 36.80M
Depreciation 0.42M 0.18M 0.05M 0.04M 0.00M
Sale purchase of stock 1.16M 100.86M -30.00M - -
Other cashflows from financing activities 0.90M 1.87M 133.53M -0.10M 37.80M
Change to netincome 28.65M 26.19M 5.91M 1.31M 4.35M
Capital expenditures 0.44M 1.05M 0.00M 0.10M 0.06M
Cash flows other operating 5.49M -5.13M -4.43M - -
Cash and cash equivalents changes -77.69M -157.49M 251.80M - -
Change in working capital -1.78M 16.13M 3.24M 0.74M 1.46M
Stock based compensation 28.59M 22.69M 5.21M 0.67M 0.58M
Other non cash items 1.75M 1.41M 0.70M 0.64M 0.13M
Free cash flow -185.49M -125.60M -52.62M -33.52M -20.78M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PRAX
Praxis Precision Medicines Inc		 8.62
2.55%		 346.21 - - 385.19 13.53 352.99 -6.86
NVO
Novo Nordisk A/S		 0.41
1.00%		 41.10 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -0.86
0.16%		 547.03 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 43.35
4.73%		 959.41 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Praxis Precision Medicines Inc

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

99 High Street, Boston, MA, United States, 02110

617 300 8460

https://praxismedicines.com

82

Name Title Year Born
Mr. Marcio Souza M.B.A. Pres, CEO & Director 1980
Ms. Nicole Sweeny Chief Commercial Officer 1975
Dr. Steven Petrou B.Sc. (Hons.), Ph.D. Co-Founder & Chief Scientific Officer NA
Mr. Timothy Edwin Kelly CFO & Treasurer 1973
Lauren Mastrocola VP of Fin. & Principal Accounting Officer NA
Dr. Karl Hansen Ph.D. Chief Technical Operations Officer NA
Alex Kane VP of Investor Relations & Corp. Communications NA
Mr. Alex Nemiroff J.D. Gen. Counsel & Sec. 1979
Ms. Kelly McCue Chief People Officer NA
Ms. Alyssa J. S. Wyant Chief Regulatory & Quality Officer 1975

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…